International Journal of
Reproductive Biomedicine
Mon, May 13, 2024
[Archive]
Volume 3, Issue 2 (7-2005)
IJRM 2005, 3(2): 51-61 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aflatoonian A, Bidgoli T K. Prevention is the ideal treatment of OHSS!!!. IJRM 2005; 3 (2) :51-61
URL: http://ijrm.ir/article-1-40-en.html
URL: http://ijrm.ir/article-1-40-en.html
Abstract: (4001 Views)
Ovarian hyperstimulation syndrome (OHSS) is a unique iatrogenic complication of controlled ovarian stimulation (COH)/in vitro fertilization (IVF) in reproductive endocrinology occurring during the luteal phase or early pregnancy. It can have a serious impact on the patient�s health. With the expansion of the assisted reproductive techniques (ART) from 1978, the incidence of OHSS is increasing worldwide.OHSS is characterized by gastrointestinal symptoms, ovarian enlargement, fluid shift to the third space, and hemoconcentration. Severe cases are associated with thromboembolic phenomena, respiratory distress, liver dysfunction and renal failure. OHSS is more common among woman who are young, thin and have PCOS or multiple allergies. Vascular endothelial growth factor (VEGF) and other cytokines are pivotal in the pathogenesis of OHSS. In the prevention of any disease, it should be emphasized that the possibility of primary prevention depends on two main requirements, first, the etiology of the disease and predisposing factors; and second, it must be feasible to avoid or manipulate such factors as paint of a prevention strategy. This strategy for preventing OHSS and its severity have included prediction of women at risk; the first step in prevention is identification of patients at risk by the recognition of risk factors. As this is not always possible, there are several ways of avoiding developing of the syndrome. The stimulation phase has to be carefully monitored (regular ultrasound and estradiol measurements), and further interventions need to be implemented if signs of hyper-response are present. The aim of this systemic review of the literature is to answer this question: �can we prevent severe OHSS�. Canceling the cycle, modification of method to trigger ovulation administration of macromolecules, coasting approach, timed unilateral or bilateral aspiration of one or two ovaries performed before or after hCG administration, In vitro maturation (IVM), elective cryopreservation of all embryos, and laser or electrocautery of one or both ovaries, have been showed to be associated with a reduced risk of OHSS by some research groups. The effect of combined method should be assessed. Finally, apart from canceling, none of these approaches was totally efficient, although most of the above-mentioned methods decrease the incidence in patients at high risk of OHSS, but overall �prevention is the ideal treatment of OHSS�.
Type of Study: Original Article |
References
1. Rydbery E and Pedersen-Bjeryaard K. Effect of serum gonadotrophin and chorionic gonadotrophin on the human ovary. JAMA 1943; 121: 1117-1122. [DOI:10.1001/jama.1943.02840140001001]
2. Estebun-Altririba I. le syndrome d'hyperstimulation massive de ovaries, Rev. Francaise de gynecologie et d' obstetriqe 1961;7-8:555-564.
3. Le Dull R. Le Syndrome d'hyperstimulaion massive des deux ovaries par injection intempestiuve d'hormones gonadotope. These paris, 1957 no.915.
4. WHO Hugues JN. Ovarian stimulation for ART in vayena. E Rower P J and Griffin PD (eds) Current practices and contravesies in ART. WHO, Geneva, Switzerland, pp 102-125.
5. Brinsden. PR. Diagnosis, Prevention and management of OHSS. Br J OB,GYN 1995;102:767-772. [DOI:10.1111/j.1471-0528.1995.tb10840.x] [PMID]
6. Abramov Y, Elchalal U and Schenker J G. Severe OHSS An "epidemic" of severe OHSS of a price to pay? Hum Reprod 1999;14: 2181-2185. [DOI:10.1093/humrep/14.9.2181] [PMID]
7. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Valerie V, Steirteghem AV, Devroey P. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Rep 2005; 20:636-641. [DOI:10.1093/humrep/deh638] [PMID]
8. Muthur Rajneesh S, Akande A Valentine, Keay Stephen D, Hunt Linda P, Jenkins Julian M. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:901-907 [DOI:10.1016/S0015-0282(00)00492-1]
9. Golan A, Ron-El R, Soffery, Weinraub Z and Caspi. Ovarian hyperstimulation syndrome: an update review. Obstet. Gynecol. Surv. 1989;44:430-440. [DOI:10.1097/00006254-198906000-00004] [PMID]
10. Navot D, Relon A, Birkenfeld A, Rabinowitz R, Brzezinski A and Margalioth Ej. Risk factors and prognostic variables in the OHSS. Am J Obstet.Gynecol 1988;159:210-215. [DOI:10.1016/0002-9378(88)90523-6]
11. Enskog A, Henriksson M, Unander M, Nilsson L, Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom OHSS developed during COH for IVF. Fertil Steril 1999; 71:808-814. [DOI:10.1016/S0015-0282(99)00090-4]
12. Delvingne A, Demoulin A, Smitz J, Donnez j, Koninckx P, Dhont M, Englert Y, et al. The ovarian hyperstimulation syndrome in IVF: a Belgian multicentric study. Clinical and biological features. Hum Reprod 1993;8: 1353-1360. [DOI:10.1093/oxfordjournals.humrep.a138260] [PMID]
13. Rabav E, David A, Serr DM, Mushiach S and Lunenfeld B. HMG for anovulation and sterility. Am J OB.GYN 1967;98:92-98. [DOI:10.1016/0002-9378(67)90137-8]
14. Rizk B and Aboulghar MA. Classificaiton/ pathophysilogy and management of OHSS in brinsdenp (ed) IVF and ART. The Parthenon publishing group new york, London, pp.131-155.
15. Mcclure N, Leya J, Radwanska E, Rawins R and Haning RV. Luteal phase support and OHSS. Hum Reprod 1992; 7:758-764. [DOI:10.1093/oxfordjournals.humrep.a137733] [PMID]
16. Asimina T, Pelicer A. in "ovulation Induction". Caroline Chaine, Paris, Elsiver, 2002; 239-267.
17. Pellicer A, Albert C Mercader A, Bonilla Musoles F, Remohi J, Simon C. The pathogenesis of OHSS in vivo studies investigating the role of ILb, IL6 and VEGF. Fertil Steril 1999; 71: 482-489. [DOI:10.1016/S0015-0282(98)00484-1]
18. Buyalos RP, Lee Ct. polycystic ovary syndrome: pathophysiology and outcome with IVF. Fertil Steril 1996; 65:1-10. [DOI:10.1016/S0015-0282(16)58017-0]
19. Haning RV Jr, Austin CW, Carlson IH. Plasma estradiol is superior to ultrasound and ovinary estriol glucuronide as a predictor of ovarian hyperstimulaiton during induction of ovulation with menotropin. Fertil steril 1983; 40:31-36. [DOI:10.1016/S0015-0282(16)47173-6]
20. Wheelan JG, Valhos NF. The ovarion hyperstimulaion syndrome is. Fertil Steril 2000; 73:883-896. [DOI:10.1016/S0015-0282(00)00491-X]
21. Paulson Rj, Do Ys, Hsueh WA. Ovarian rennin production in vitro and in vivo: characterization and clinical correlation. Fertil Steril 1989; 51:634-638. [DOI:10.1016/S0015-0282(16)60612-X]
22. Morris Rs, Wong Il, Kirkman E. Inhibition of ovarian derived prorenin to anjiotensin cascade in the treatment of OHSS. Hum Reprod 1995; 10:1355-1358. [DOI:10.1093/HUMREP/10.6.1355] [PMID]
23. Loret de mola JR, Baumgardner GP, Goldfarb JM. OHSS:pre-ovulatory serum concentrations of IL6, IL1 receptor antagonist and tumor necrosis factor. Alpha cannot predict it orcurrence. Hum Reprod 1996; 11:1377-1380. [DOI:10.1093/oxfordjournals.humrep.a019403] [PMID]
24. Agrawal R, Tan Sl, Wild S. Serum VEGF concentrations in IVF cycles predict the risk of OHSS. Fertil Steril 1999; 71:287-293. [DOI:10.1016/S0015-0282(98)00447-6]
25. Levin ER, Rosen Gf, Cassidenti Yee B, Meldrum D, Wisot A, Pedrom A DL. Role of VEGF in ovarian hyperstimulation syndrome. J Clin Invest 1998;1:102 (11):1978-1985. [DOI:10.1172/JCI4814] [PMID] [PMCID]
26. Nukmura Y, smith M, Krishna A. Increased number of mast cell in the dominant follicle of the cow: relation ships among luteal, stromal, and hilar regions. Bio Reprod 1987;37:546-549. [DOI:10.1095/biolreprod37.3.546] [PMID]
27. Smit G, Olutunbosun O, Delbaere A, Pierson R, Vussart G, Costagliota S. OHSS due to mutation in the FSH receptor. New Engl J Med 2003; 349: 760. [DOI:10.1056/NEJMoa030064] [PMID]
28. Flughesu AM, Villa P, Pavone V, Guido M, Apa R, Caruso A. The impact of insulin secretion on the ovarian response to exogenous gonadotrophins in PCOS. J Clin Endocrinol Metas 1997; 82:644-648. [DOI:10.1210/jcem.82.2.3727] [PMID]
29. Fabregues F, Balasch J, Manau D, Jimenez W, Arroyo V,Creus M, Rivera F, et al. Hemutocrit, Leukocyte and platelet counts and the severity of the OHSS. Hum Reprod 1998; 13:2406-2410. [DOI:10.1093/humrep/13.9.2406] [PMID]
30. Valvilis D, Tzitzimikas S, Agorastos T, Loutopoulos A, Tsalikis T and Bontis JN. Ostporacentesis bilateral massive vulvar edema in a patient with OHSS. Fertil Steril 2002; 77: 841-843. [DOI:10.1016/S0015-0282(01)03248-4]
31. Abramov Y, Elchalal V and Schenker JG. Pulmonary manifestation of severe OHSS: a multicenter study. Fertil Steril 1999;71: 645-651. [DOI:10.1016/S0015-0282(98)00528-7]
32. Khalaf Y, Anderson H, Taylor A and Bravde P. Two rare events in one patient undergoing assisted conception: empty follicle syndrome and OHSS with the sole administration of a GnRH agonist. Fertil Steril 2000;73:171-172. [DOI:10.1016/S0015-0282(99)00460-4]
33. Mozes M, Bogokowsk H, Antebi E, Lunefeld B, Rabau E, Serr DM, David A, et al. Thromboembolic phenomena after OHSS with human gonadotrophins. Lancet 1965;2:1213-1215. [DOI:10.1016/S0140-6736(65)90636-7]
34. Aboulghar MA, Mansour RT, Serour GL, Ramzy AM, Amin YM. Oocyte quality in patients with sever OHSS. Fertil Steril 1997; 68:1017-1021. [DOI:10.1016/S0015-0282(97)00409-3]
35. Gidley-baird AA, O'neill C, Sinosich Mj, Porter RN, Pike Il and Saunders DM. Failure of implantation in human IVF and ET patients: the effects of altered progesterone/estrogen ratios in human and mice. Fertil Steril 1986; 45: 69-74. [DOI:10.1016/S0015-0282(16)49099-0]
36. Chen CD, Cehn HF, Chen SU and Uang YS. Relationships of serum pro-inflammatory cytokines and VEGF with liver dysfunction in severe OHSS. Hum Reprod 2000; 15:66-71. [DOI:10.1093/humrep/15.1.66] [PMID]
37. Dulitzky M, Cohen SB, Inbal A, Seldman Ds, Soriano D, Lidor A, Mashiach S and Rabinovici J. Increased prevalence of thrombophilia among women with sever OHSS. Fertil Steril 2002; 77:463-467. [DOI:10.1016/S0015-0282(01)03218-6]
38. Engmannalm Maconochine N, Sladkevicius P, Bekir J, Campbell S and Tan SL. The outcome of IVF treatment in women with sonographic evidence of polycystic ovarian morphology. Hum Reprod 1999; 14:161-171. [DOI:10.1093/humrep/14.1.167] [PMID]
39. Abramov Yoram, Elchalal Uriel, Schenker Joseph G. Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1998; 70:1070-1075. [DOI:10.1016/S0015-0282(98)00350-1]
40. Wiser A, Levron J, Kreizer d, Achiron R, Shrim A, Schiff E, Dor j, Shulman A. Outcome of pregnancies complicated by severe ovarian hyperstimulation syndrome (OHSS): a follow-up beyond the second trimester. Hum Rep 2005; 20:910-914. [DOI:10.1093/humrep/deh713] [PMID]
41. Egbase, P E. Severe OHSS: How many cases are preventable? Hum Rep 2000; 15:8-10. [DOI:10.1093/humrep/15.1.8] [PMID]
42. Fleming R, Haxton M J, Hamilton M P R. Combined gonadotrophin-releasing hormone analog and exogenous gonadotrophins for ovulation induction in infertile women; Efficacy related to ovarian function assessment. Am J Obstet Gynecol 1988; 159:376-381. [DOI:10.1016/S0002-9378(88)80088-7]
43. Ashrafi M, Moini A, Mohammadzadeh A, Ezabadi Z, Zafarani F, Baghestani A R. A comparative study of GnRH antagonist and GnRH agonist in PCO patients undergoing IVF/ICSI cycles. Iranian J Rep Med 2005; 3:14-18.
44. Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C and Crosignani P G. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulatin syndrome. Hum Rep 2005;20: 2421-2425. [DOI:10.1093/humrep/dei074] [PMID]
45. Orvieto Raoul. Can we eliminate severe ovarian hyperstiulation syndrome? Hum Rep 2005; 20:320-322. [DOI:10.1093/humrep/deh613] [PMID]
46. Hancock K W, Stitch S N, Dakay Scott J S, Levell M J and Ellis F R. Ovulation stimulation of response to gonadotrophins. 1970. Lancet, 2:482-485. [DOI:10.1016/S0140-6736(70)90109-1]
47. Jain T, Hariow B L and Hornstein, M D. Insurance coverage and outcome of IVF. N. Engl. J Med 2002;374:661-666. [DOI:10.1056/NEJMsa013491] [PMID]
48. Chen CD, Chao KH, Yang JH, Chen SU, Ho HN, Yang YS. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimnulation syndrome. Fertil Steril 2003; 80:86-90. [DOI:10.1016/S0015-0282(03)00548-X]
49. Sher G, Zouves C, Feinmanm M and Massarani G. Prolonged coasting: An effective method for preventing sever OHSS in patients undergoing IVF. Hum Rep 1995; 10:3107-3109. [DOI:10.1093/oxfordjournals.humrep.a135867] [PMID]
50. Egbase P E, Al Sharhan M, grudzinskas J G. Early coasting in patients with polycystic ovarian syndrome is consistent with good clinical outcome. Hum Rep 2002;17: 1212-1216. [DOI:10.1093/humrep/17.5.1212] [PMID]
51. Egbase P E, Al Sharhan M, Grudzinskas J G. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Rep 1999; 14:1421-1425. [DOI:10.1093/humrep/14.6.1421] [PMID]
52. Al-Shawaf T, Zosmer A, Hussain S, Tozer A, Panay N, Wilson C, Lower A MGrudzinskas J G. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified coasting strategy based on ultrasound for identification of high-risk patients. Hum Rep 2001;16: 24-30. [DOI:10.1093/humrep/16.1.24] [PMID]
53. Lee C, Tummon I, Martin J. Does withholding gonadotrophin administration prevent severe. Hum Rep 1998;13:1157-1158. [DOI:10.1093/humrep/13.5.1157] [PMID]
54. Benadiva, C A, Davis O, Kligman I. Withholding gonadotrophin administration is an effective alternative for the prevention of OHSS? Fertil Steril 1997; 67:724-727.
55. Dhont, M, Vander Straeten, F. And De sutter, D. Preventin of severe OHSS by coasting. Fertil Steril 1998; 70:847-850. [DOI:10.1016/S0015-0282(98)00280-5]
56. Tortoriello, D.V, McGovern, PG, Colon, J M et all. Coasting does not adversely affect cycle outcome in a subset of highly responsive IVF patients. Fertil Steril 1998; 69: 454-460. [DOI:10.1016/S0015-0282(97)00560-8]
57. Mansour R, Aboulghar M, Serour G, Amin Y, Abou-Setta AM.. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome..Human Reproduction2005. ;20: 3167-3172 [DOI:10.1093/humrep/dei180] [PMID]
58. Waldenstrom U, Kahn J, Marsk L and Nilsson S. High pregnancy and successful prevention of severe OHSS by prolonged coasting of very hyperstimulated patients: a multi center study. Hum Rep 1999; 14:294-297. [DOI:10.1093/humrep/14.2.294] [PMID]
59. Egbase P E, Al sharhan M, Grudzink as J C. Early unilateral follicular aspiration compared to coasting for the prevention of sever OHSS: a prospective randomized study. Hum Rep 1999; 14:1421-1425. [DOI:10.1093/humrep/14.6.1421] [PMID]
60. Aflatoonian A. Comparison of coasting and follicular aspiration for prevention of OHSS in ART cycles. Presented in 13th world congress on IVF/ Assisted Reproductive Genetics. (May-2005) Istanbul,Turkey
61. Mural A, Silvina B, Estella J, Jacob M, Lavrel S, Sergio O. Effect of coasting on the implantation potential of embryos transfer after cryopreservation and thwing. Fertil Steril 2005; 84:867-874. [DOI:10.1016/j.fertnstert.2005.03.069] [PMID]
62. Navot D, Bergh P A, Laufer N. OHSS in novel reproductive technologies; prevention and treatment. Fertil Steril 1992; 58:249-261. [DOI:10.1016/S0015-0282(16)55188-7]
63. Aboulghar M, Mansour R T, Serour G I, Elattar I and Amin Y. Follicular aspiration does not protect agonist the development of OHSS. J Assist Reprod Genet 1992; 9:236-243. [DOI:10.1007/BF01203820] [PMID]
64. Tomazevic T and Meden Vrtove CH. Early timed follicular aspiration prevent sever OHSS. J Assisted Reprod Genet 1996; 13:282-286. [DOI:10.1007/BF02070139] [PMID]
65. Egbase P E, Madhseed M, Al Sharhan M, grudzinskas J G. Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. Hum Rep 1997; 12:2603-2606. [DOI:10.1093/humrep/12.12.2603] [PMID]
66. Aflatoonian A, Karymzadeh mibodi M A, Dehghani-Firoozabadi R, Taheri Panah R, Kalantar S M, Amir Arjmand M H, Solimani M. The role of aspiration of half of ovarian follicles prior to administration of hCG or GnRH-a for prevention of severe OHSS in ART programs. Middle East Fertility Society Journal 2000; 5(1):73-75.
67. Schroder Annika K, Schopper Beate, Al-Hasani safaa, Diedrich Klaus, Ludwig Michael. Unilateral follicular aspiration and in-vitro maturation before contralateral oocyte retrieval: a method to prevent ovarian hyperstimulation syndrome. European J Obstet Gynecol 2003; 110:186-189. [DOI:10.1016/S0301-2115(03)00273-2]
68. Oyawoye OA, Chander B, Hunter J, Abdel GA. Prevention of ovarian hyperstimualtion syndrome by early aspiration of small follicles in hyper-responsive patients with polycystic ovaries during assisted reproductive treatment cycles. Available in Medscape General Medicine 2005; 7(3).
69. Gnoen Y, Powell WA. Casper RF. Effect of follicular aspiration or hormonal parameters in patients undergoing ovarian stimulation. Hum Reprod 1991; 6:356-358. [DOI:10.1093/oxfordjournals.humrep.a137338] [PMID]
70. Jarvela I, Nuojua-Huttunen S, Martikainen H. Ovulation side and cycle fecundity: a retrospective analysis of frozen/thawed embryo transfer cycles. Hum Rep 2000; 15:1247-1249. [DOI:10.1093/humrep/15.6.1247] [PMID]
71. Fukuda M, Fukuda K, Andersen C Y and Byskov A G. Right-sided ovulation favours pregnancy more than left sided ovulation. Hum Reprod 2000; 9:1921-1926. [DOI:10.1093/humrep/15.9.1921] [PMID]
72. Chian Ri-Cheng, Buckett William M, Ahmad Kamal Abdoul Jalil, Weon-Young Son, Camille Sylvestre, Durga Rao and Seang Lin Tan. Natural-cycle in vitro fertilization combined with in vitro maturation of immature oocytes is a potential approach in infertility treatment. Fertil Steril 2004; 82 (6). [DOI:10.1016/j.fertnstert.2004.04.060] [PMID]
73. Orvieto R, Ben-Rafael Z. Role of intravenous albumin in the prevention of sever OHSS. Human Reprod 1998; 13:3306-3309. [DOI:10.1093/humrep/13.12.3306] [PMID]
74. Aboulghar M, Evers L H, Ai inany H. Intravenous albumin for preventing severe OHSS. The Cochrane Database of systemic Reviews 2005; Issue 4.
75. Committee on safety of medicines. The safety of human albumin 1999. Current Prob. Pharmacovigilance 1999; 25:11.
76. Konig E, Bussen S, Sutterlin M, Steck T. Prophylactic intravenous hydroxyethyle starch solution prevents moderale-severe OHSS in IVF patients: a prospective randomized, double-blind and placebo-controlled study. Hum Rep 1998; 13: 2421-2424. [DOI:10.1093/humrep/13.9.2421] [PMID]
77. T Sunodo, T. Shibahara H, Hirano Y, Suzuki T. Treatment for OHSS using an oral dopamine prodrug docarpamine. Gynecological Endocrinology 2003; 17(4):281-286. [DOI:10.1080/713603291] [PMID]
78. Homburg R. Clomiphen citrate end of an era? A mini-review. Hum Reprod 2005: 20(8):2043-2051. [DOI:10.1093/humrep/dei042] [PMID]
79. Available in internet: Novartis warns doctors on off labled femara (letrozole). Medscape. Routers news Zorich December 2005.
80. Casper, R F. Ovarian hyperstimulation syndrome. GnRH analog, Does triggering ovulation with GnRH analog prevent severe OHS? Hum Reprod 1996; 11:1144-1146. [DOI:10.1093/oxfordjournals.humrep.a019340] [PMID]
81. Abdalla H L. Ah-Moye M, Brinsden P. Howe D L, Olonofoa F Craft I. The effect of the dose of hCG and the typer of gonadotrophin stimulation on oocyte recovery rates in an IVF program. Fertil Steril 1987; 48:958-963. [DOI:10.1016/S0015-0282(16)59591-0]
82. Whelan J G and Vlahos N F. the ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:883-896. [DOI:10.1016/S0015-0282(00)00491-X]
83. Chang P, Kenley S, Burns T, Denton G, Currie K Devance G and O Dea L. Recombinant hCG in ART: results of a clinical trial compareing two doses of rhCG (ovid rel) to hCG (profasi) for induction of final follicular maturation in IVF-ET. Fertil Steril 2001; 76:67-74. [DOI:10.1016/S0015-0282(01)01851-9]
84. The Europear rLH study group. Human recombinant is as effective as: but safer than, uhcg in inducing final maturation and ovulation in IVF procedures Results of multicenter double-blind stuey. J Clin Endocrinol Metab. 2001; 86:2607-2618. [DOI:10.1210/jc.86.6.2607]
85. Shahar K. Luteolysis induced by a GnRH agonist is the key to prevention of OHSS. Fetil Steril 2004; 81(1):1-5. [DOI:10.1016/j.fertnstert.2003.05.032] [PMID]
86. Shalev E, Geslevich Y,Ben-Ami M. Induction of preovulatory LH surge by GnRH agonist for women at risk of developing the OHSS. Hum Reprod 1994; 9:417-419. [DOI:10.1093/oxfordjournals.humrep.a138520] [PMID]
87. Diane DN, Katheline M, Eric Van R, Miet VS, Jan G. Singleton pregnancies are as affected by ovarian hyperstimulation syndrome as twin pregnancies. Fertil Steril 2004; 82:6. [DOI:10.1016/j.fertnstert.2004.07.945] [PMID]
88. Pritts EA and Atwood A K. Luteal phase support in infertility treatment: a neta-analysis of the randomized trials. Hum Rep 2002; 17:2287-2299. [DOI:10.1093/humrep/17.9.2287] [PMID]
89. Beckers NS, Eijkeman Mj, Ludwig M, Felberbaum R. Non supplemeted luteal phase characteristics after the administration of rhcG, rLH, or GnRH agonist to induced final oocyte maturation in IVF patients after ovarian stimulation with rFSH and GnRh antagonist cotreatment. J. Clin Endocrinol Metab 2003; 88:4186-4192. [DOI:10.1210/jc.2002-021953] [PMID]
90. Arau Jo, E Jr, Bernardini, Frederick J L. Asch RH andBalmaceda J P. Prospective randomized comparison of hCG versus i.m. progesterone for luteal phase support in ART. J Assis Reprod Genet 1994; 11:74-78. [DOI:10.1007/BF02215991] [PMID]
91. Herman A, Ron-El R, Golan A, Raziel A, Soffer y and Caspi E. Pregnancy rate and OHSS after luteal hCG in IVF stimulation with GnRH analog and monotropins. Fertil Steril 1999; 53:92-96. [DOI:10.1016/S0015-0282(16)53222-1]
92. Penzias A S. Luteal phase support. Fertil Steril 2002; 77:318-323. [DOI:10.1016/S0015-0282(01)02961-2]
93. Schwarzler P. Abendstein BJ, Klingler A, Kreuzer E, Rjosk HK. Prevention of severe OHSS in IVF patients by steroidal ovarian suppression a prospective randomized study. Hum Fertil 2003; 6(3):125-129. [DOI:10.1080/1464770312331369383] [PMID]
94. Pirard C, Donniz J, Loumaye E. GnRH agonist as novel luteal support: result of a randomized, parallel group, l feasibility study using intranasal administration of buserelin. Hum Reprod 2005; 20(7):1798-1808. [DOI:10.1093/humrep/deh830] [PMID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
